Delcath SystemsDCTH
DCTH
About: Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
Employees: 76
0
Funds holding %
of 7,407 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
275% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 8
178% more call options, than puts
Call options by funds: $2.03M | Put options by funds: $730K
154% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 13
81% more capital invested
Capital invested by funds: $90.9M [Q3] → $165M (+$73.8M) [Q4]
33% more funds holding in top 10
Funds holding in top 10: 3 [Q3] → 4 (+1) [Q4]
30% more funds holding
Funds holding: 69 [Q3] → 90 (+21) [Q4]
5.64% more ownership
Funds ownership: 37.16% [Q3] → 42.8% (+5.64%) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$24
106%
upside
Avg. target
$24
106%
upside
High target
$24
106%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Swayampakula Ramakanth 23% 1-year accuracy 44 / 192 met price target | 106%upside $24 | Buy Maintained | 7 Mar 2025 |
Financial journalist opinion
Based on 5 articles about DCTH published over the past 30 days
Positive
Zacks Investment Research
1 week ago
Delcath Systems (DCTH) Soars 9.8%: Is Further Upside Left in the Stock?
Delcath Systems (DCTH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Neutral
Business Wire
1 week ago
Delcath Systems Announces Publication of Comparative Analysis from Randomized Portion of FOCUS Study in Metastatic Uveal Melanoma
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of a comparative analysis from the randomized cohort of the Company's Phase 3 FOCUS study in Annals of Surgical Oncology. The study, titled “An Open-label, Randomized Study of Melphalan/Hepatic Delivery System Versus Best Alternative Care in Patients with Unresectable Metastatic Uveal Melanom.
Negative
Seeking Alpha
2 weeks ago
Hospitals Experience FOMO In Adopting Delcath's PHP Treatment
Delcath Systemsbeat Q4 sales estimates. This was driven by increased adoption of HEPZATO KIT. However, the stock fell due to the Biotech/Medtech bear market. Delcath reported its first profitable quarter with adjusted EBITDA of $4.6 million. It has a strong cash position which will be used for its two Phase 2 trials. European expansion faces reimbursement challenges, but growing usage & the CHOPIN trial could turn the tide.
Positive
Zacks Investment Research
3 weeks ago
Wall Street Analysts See a 58.49% Upside in Delcath Systems (DCTH): Can the Stock Really Move This High?
The mean of analysts' price targets for Delcath Systems (DCTH) points to a 58.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Neutral
Business Wire
3 weeks ago
Delcath Systems to Participate at the Canaccord Genuity Horizons in Oncology Virtual Conference
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will participate in the CG Horizons in Oncology Virtual Conference on April 7, 2025 at 10:00 a.m. ET. Investors interested in participating should contact their Canaccord representative. About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT Delcath Systems, Inc. is an interventional on.
Neutral
Business Wire
1 month ago
Delcath Systems, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as material inducements to six individuals whose employment commenced in January and February of 2025. The grants resulted in the right to purchase 264,000 shares of the Company'.
Neutral
Seeking Alpha
1 month ago
Delcath Systems, Inc. (DCTH) Q4 2024 Earnings Call Transcript
Delcath Systems, Inc. (NASDAQ:DCTH ) Q4 2024 Earnings Conference Call March 6, 2025 8:30 AM ET Company Participants David Hoffman - General Counsel, Corporate Secretary & Chief Compliance Officer Gerard Michel - CEO Sandra Pennell - SVP, Finance Kevin Muir - General Manager, Interventional Oncology Vojislav Vukovic - Chief Medical Officer Conference Call Participants John Newman - Canaccord Genuity Corp Marie Thibault - BTIG Sudan Loganathan - Stephens Bill Maurer - ClearStreet Yale Jen - Laidlaw & Company Chase Knickerbocker - Craig-Hallum Capital Group Swayampakula Ramakanth - H.C. Wainwright Operator Greetings and welcome to the Delcath Systems' Fourth Quarter 2024 Earnings Conference Call.
Positive
Zacks Investment Research
1 month ago
Delcath Systems, Inc. (DCTH) Beats Q4 Earnings and Revenue Estimates
Delcath Systems, Inc. (DCTH) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of a loss of $0.10 per share. This compares to loss of $0.48 per share a year ago.
Neutral
Business Wire
1 month ago
Delcath Systems Reports Fourth Quarter and Full Year 2024 Results
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported financial results and business highlights for the fourth quarter and full year-ended December 31, 2024. Fourth Quarter and Full Year 2024 Financial Results Total fourth quarter and full year revenue of $15.1 million and $37.2 million, respectively HEPZATO KIT™ fourth quarte.
Neutral
Business Wire
1 month ago
Delcath Systems to Host Fourth Quarter and Full Year 2024 Earnings Call
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on March 6, 2025, at 8:30 AM Eastern Time to discuss results for its fourth quarter and full year ended December 31, 2024. Conference Call Information To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call. Event Date: Thursd.
Charts implemented using Lightweight Charts™